Plain-English translation of NCT07134842 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Glioblastoma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
WinGlio is testing whether a medication called ipilimumab can be safely given to newly diagnosed glioblastoma patients before they receive their standard brain cancer treatment. The immunotherapy medication works by helping your immune system recognize and fight cancer cells. Researchers want to see if giving this treatment early—before surgery and chemotherapy—is safe and might help control the disease.
Glioblastoma is a very aggressive brain cancer, and current treatments have limited success. This trial explores whether using an immune-boosting medication before standard treatment could improve outcomes by preparing the body's immune system to fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive up to two cycles of immunotherapy, with each cycle lasting 21 days, before proceeding to your standard brain cancer treatment (surgery and chemotherapy). During this time, you'll have scheduled visits for medical check-ups, blood tests, and imaging scans to monitor your response and safety. After completing the immunotherapy, you would continue with your doctor's recommended standard treatment plan.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United Kingdom